Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.76 USD | +1.50% | +26.12% | -23.70% |
May. 13 | JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating | MT |
May. 10 | Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.70% | 770M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- PRME Stock
- News Prime Medicine, Inc.
- Guggenheim Cuts Prime Medicine's Price Target to $20 From $24, Maintains Buy Rating